Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2025-04-28 Regulatory Filings
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-04-28 English
Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises
Regulatory Filings Classification · 100% confidence The document is a press release dated April 26, 2025, from Valneva SE. It provides an update regarding the French health authority's (HAS) recommendation concerning their Chikungunya vaccine (IXCHIQ®) following reports of serious adverse events in elderly patients. The text details the regulatory action taken (suspension of use for 65+), the company's response, and includes background information on the disease and the company. This format—a formal announcement detailing recent operational/regulatory news, often including management commentary and forward-looking statements—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate news. Since it is not a full quarterly report (IR) or an official regulatory filing form (like 10-K), and it focuses on a specific, time-sensitive operational/regulatory event (vaccine use update), it aligns best with an Earnings Release (ER) which often includes material updates outside of standard financial reporting periods, or a Regulatory Filing (RNS) if it were less specific. Given the content is a detailed update on a product's regulatory status and public health response, it functions as a material corporate announcement. However, since it is not explicitly an 'Earnings Release' (which usually focuses on financial results), and it is a specific announcement about a regulatory/product matter, it fits well into the general 'Regulatory Filings' (RNS) category as a fallback for material announcements not covered elsewhere, or potentially an 'LTR' if the adverse event reporting was framed as a legal/regulatory investigation. Given the context is a direct response to a public health authority's decision regarding a vaccine, it is a significant regulatory/product update. Since there is no specific category for 'Product Regulatory Update', and it is not a full report, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fit, although 'ER' is often used for major non-financial announcements too. I will select RNS as the most general fit for a material, non-financial press release update.
2025-04-26 French
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 26, 2025, titled "Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities." It details a regulatory/health authority decision (HAS in France) regarding the use of their vaccine (IXCHIQ®) following reports of serious adverse events (SAEs). This type of communication, which provides an update on a specific health/regulatory matter concerning a product, fits best under the general category of Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if it were about a lawsuit, but here it is a direct update on regulatory/safety surveillance. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it concerns a specific regulatory/safety development, RNS (Regulatory Filings) is the most appropriate general classification for non-standard announcements. It is not a formal declaration of voting results (DVA), director dealing (DIRS), or a capital change (CAP). Given the nature of the announcement—a company responding to a public health authority's decision regarding product use—RNS serves as the best fit among the provided options for a significant, non-financial regulatory update.
2025-04-26 English
6-K
Regulatory Filings
2025-04-18 English
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Regulatory Filings Classification · 100% confidence The document is a press release dated April 18, 2025, from Valneva SE announcing an update regarding the ACIP recommendation for its chikungunya vaccine, IXCHIQ®. It details the committee's voting outcomes, safety concerns (SAEs), and ongoing monitoring. This type of announcement, which communicates key operational and regulatory updates outside of a formal periodic financial report (like 10-K or IR), typically falls under a general regulatory announcement or an earnings-related communication. Since it is not a full transcript (CT), a formal financial report (10-K/IR), or a specific management discussion (MDA), it best fits the category for general regulatory announcements or press releases that convey important, timely information. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-financial-statement-specific update, although 'Earnings Release' (ER) is sometimes used for major news, this is specifically a regulatory/medical update. However, since it is a press release announcing a specific regulatory committee's decision and safety profile update, it functions as a material event disclosure. In the absence of a specific 'Material Event Disclosure' code, RNS serves as the best fit for a general, non-financial-report regulatory update.
2025-04-18 English
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya
Regulatory Filings Classification · 100% confidence The document is a press release dated April 18, 2025, from Valneva SE. It announces an update regarding the ACIP's recommendation for their IXCHIQ® vaccine against chikungunya, detailing the maintained recommendation for travelers and a precautionary note for individuals aged 65 and over following a review of adverse events reported via VAERS. This content—an update on a product's regulatory/advisory status and associated safety monitoring—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on a specific, timely operational/product update rather than comprehensive quarterly financials (IR) or a formal regulatory filing (10-K/AR), and it is a direct announcement of news, 'Earnings Release' (ER) is the most appropriate fit among the options, as these often contain operational highlights and product news outside of formal quarterly reporting periods. It is not a transcript (CT), a formal report (10-K, IR), or a proxy statement (DEF 14A). Given the nature of the announcement (product update/safety news), ER is selected.
2025-04-18 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.